Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion

The proposed acquisition brings leading sickle cell disease expertise to Pfizer with potential combined worldwide peak sales of more than $3 billion to address the full spectrum of critical needs in the underserved sickle cell community Transaction valued at $68.50 per Global Blood Therapeutics share in cash, for a total enterprise value of approximately $5.4 billion.

Read More